<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490308</url>
  </required_header>
  <id_info>
    <org_study_id>870/070</org_study_id>
    <nct_id>NCT00490308</nct_id>
  </id_info>
  <brief_title>The Influence of Estradiol Supplementation During the Luteal in Patients Undergoing IVF Treatment</brief_title>
  <official_title>Blinded Randomised Trial About the Influence of Estradiol Supplementation During the Luteal in Patients Undergoing in Vitro Fertilization (IVF) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether treatment with Estradiol supplementation during the luteal phase improves
      IVF outcomes

      Patients undergoing IVF treatment with controlled ovarian hyperstimulation using a GnRH
      analog will receive 4 mg estradiol valerate in the luteal phase.Patient's followup will
      include E2 progesterone and BHCG 14 days after embryo transfer and vaginal ultrasound on day
      21 and 28 after embryo transfer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include Patients undergoing IVF treatment with controlled ovarian
      hyperstimulation using a daily GnRH analog in a long protocol,older then 18, .The women will
      be randomised to two groups.Both groups will be given vaginal tabs of natural micronized
      progesterone(Uterogestan)

      The study group will be given oral estradiol Valerate 4 mg.Prior to treatment, each patient
      will be signed on informed concent.

      Patients will be excluded if they are older than 40, have any systemic illnesses or a
      personal or family history of a thromboembolic event.

      Follow up:

      Verification of pregnancy status and hormonal profile will be carried out on day fourteen
      after embryo transfer by means of serum hCG,P and E2. clinical pregnancy will be defined as
      the presence of a gestational sac on ultrasonography on day 21 after embryo transfer and
      fetal heart will be evaluated on day 28
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">August 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <secondary_outcome>
    <measure>E2 and progesterone levels</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Infertility</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment with estradiol valerate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women treated for infertility with controlled ovarian hyperstimulation using daily
             GnRH agonist

        Exclusion Criteria:

          -  Women younger then 18 or older then 40

          -  Women with systemic disease

          -  Women with a family or personal history of thromboembolic event
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rephael Ron-el, profesor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf-Harofeh Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ran Svirsky, MD</last_name>
    <phone>+972-0523-859521</phone>
    <email>rsvirs@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Infertilty unit, Assaf-Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>ran svirsky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>mori shecter, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <last_update_submitted>June 24, 2007</last_update_submitted>
  <last_update_submitted_qc>June 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2007</last_update_posted>
  <keyword>luteal</keyword>
  <keyword>phase</keyword>
  <keyword>estradiol</keyword>
  <keyword>pregnancy</keyword>
  <keyword>rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

